P3-GemOx as a novel immunochemotherapy candidate in NK/T-cell lymphoma management.

ABSTRACT:

Introduction

Natural killer/T-cell lymphoma (NKTL) is a rare disease that shows suboptimal responses to existing therapies. This study reports the efficacy of the P3-GemOx regimen compared to the traditional PP-GemOx regimen in advanced NKTL.

Methods

Eleven patients received the P3-GemOx regimen [mitoxantrone hydrochloride liposome (Plm60) combined with PP-GemOx (anti-PD-1 antibody, pegaspargase, gemcitabine, and oxaliplatin)] every 3-4 weeks, with a median of 3 cycles (range: 1-4). Another eleven patients received the PP-GemOx regimen every 3-4 weeks, with a median of 4 cycles (range: 2-6). Treatment response was assessed using 18F-FDG-PET with CT or MRI.

Results

All patients treated with P3-GemOx responded, with nine achieving complete remission (CR) and two partial

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC12588983 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature